Company Description
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases.
The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence.
Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.
The company is headquartered in Alameda, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Adam Mendelsohn Ph.D. |
Contact Details
Address: 1350 S. Loop Road Alameda, California 94502 United States | |
| Phone | 818-833-5000 |
| Website | vivani.com |
Stock Details
| Ticker Symbol | VANI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001266806 |
| CUSIP Number | 92854B109 |
| ISIN Number | US92854B1098 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Adam Mendelsohn Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Brigid Ann Makes | Chief Financial Officer |
| Truc Le M.B.A. | Chief Operations Officer |
| Dr. Lisa E. Porter M.D. | Chief Medical Officer |
| Donald Dwyer M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| May 3, 2024 | EFFECT | Notice of Effectiveness |
| May 2, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 22, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 26, 2024 | 10-K | Annual Report |